GLP1 agonists Expert Views

Dr. Simon Stott discussed the potential of GLP-1 agonists, like exenatide and lixisenatide, in treating Parkinson's disease. He highlighted that in a study, patients on exenatide showed initial improvement in symptoms and maintained this level for 48 weeks, unlike those on a placebo whose symptoms worsened. After stopping the drug, researchers observed the effects during a 'washout' period. Another study in France with lixisenatide, involving over 150 participants across 23 sites, also showed promising results, with a slowing of motor progression in patients.

GLP1 agonists, originally approved for diabetes and obesity due to their ability to regulate blood sugar and promote weight loss, are now being explored for Parkinson's disease. Laboratory models suggest these drugs might have protective benefits for Parkinson's. Researchers have conducted initial trials using a GLP1 drug called exenatide, with some studies funded by the Michael J. Fox Foundation. This research is part of a broader effort to find new therapeutic options for Parkinson's.

Professor Olivier Rascol discussed the findings from the LixiPark trial, which studied the effects of lixisenatide, a GLP-1 receptor agonist, on Parkinson's disease. He noted that these drugs might have anti-inflammatory properties that could help protect neurons in the brain. Specifically, they may counteract the harmful effects of impaired insulin signaling in the brain, which can lead to inflammation and neuronal death. The trial results suggest that lixisenatide may delay the progression of motor symptoms in Parkinson’s disease.

Professor Olivier Rascol discussed the findings of the LixiPark trial, which tested lixisenatide, a GLP-1 receptor agonist, for Parkinson's disease. The trial showed that lixisenatide might delay the progression of motor symptoms in Parkinson’s. This is significant because it builds on earlier positive results from a similar drug, exenatide, tested in 2017. Rascol also highlighted that newer GLP-1 agonists, like lixisenatide, are more convenient for patients as they require less frequent administration, such as weekly instead of daily injections.

GLP-1 agonists, such as exenatide, have been studied for their potential benefits in Parkinson's disease. Early trials suggested these drugs might slow the disease's progression, but a recent large phase three trial in the UK found no measurable benefits. The expert highlights challenges in testing these drugs, such as their effects like weight loss, which make it hard to conduct blinded studies. Despite the disappointing trial results, there are still open questions and ongoing research to understand the earlier signals and the complexity of testing these drugs for Parkinson's.

Dr. Michele Tagliati, Director of the Movement Disorders Program at Cedars-Sinai Medical Center, shared his excitement about the potential of GLP-1 agonists, specifically Liraglutide, for treating Parkinson's disease. He mentioned that Cedars-Sinai is conducting a trial involving 57 patients, where participants are randomized in a two-to-one ratio to receive either the active medication or a placebo. The trial aims to complete recruitment by summer 2018 and expects results by the end of 2019. Dr. Tagliati expressed gratitude to Cure Parkinson's Trust for their support, emphasizing that their initiative was crucial for the trial's existence.

Professor Tom Foltynie discusses the use of GLP-1 agonists, specifically exenatide, in Parkinson's disease treatment. He highlights the exclusion criteria for trials, such as patients who are underweight, have significant dementia, depression, or have undergone deep brain stimulation. He also mentions concerns about pancreatitis, although large studies have not shown increased risk with exenatide. Foltynie notes that while diabetes patients are excluded from trials, they might benefit the most from the treatment as it could address both diabetes and Parkinson's.

Dr. Richard Wyse discusses the promising results of trials involving GLP-1 agonists, a class of drugs being tested for Parkinson's disease. He highlights the significance of these trials, particularly one involving the drug exenatide, which has shown notable findings. The results were published in the prestigious New England Journal of Medicine, underscoring their importance. Dr. Wyse emphasizes the collaborative effort in designing these trials and the potential impact on Parkinson's treatment.

Dr. Michael Okun discusses the potential of GLP1 agonists, originally diabetes medications, in treating Parkinson's disease. He notes that early studies, particularly with the drug exenatide, showed promising results in laboratory models and imaging studies. However, later studies were less convincing, highlighting challenges in study design and variability in Parkinson's disease stages and medication status. Dr. Okun emphasizes the complexity of Parkinson's research and encourages viewers to stay informed about upcoming study results.

Dr. Ramon Rodriguez discusses the potential of GLP-1 agonists, medications originally used for diabetes, to slow the progression of Parkinson's disease. He highlights that these drugs are already approved for diabetes, providing a wealth of safety data. However, he notes challenges in recruiting participants for clinical trials, as many eligible candidates are hesitant to join. Dr. Rodriguez emphasizes the importance of these studies in advancing towards a cure for Parkinson's.